Biogen

Biogen

Team Size
1–10
Employees
Xconomy

Eisai & Biogen Reveal Promising Alzheimer’s Data, But Questions Linger

Health Science People
Xconomy

Biogen Makes Another Small Bet With Option Deal for TMS Stroke Drug

Health
Xconomy

SMA Day: AveXis Gene Therapy Creeps Forward as Biogen Drug’s Sales Slow

Health Science
Bloomberg Business

Biogen's Strange MS Quandary Requires Stronger Medicine

Health Earnings
Xconomy

Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs

Health Strategy
Bloomberg Business

Biogen Drops After Alzheimer's Drug Trial Change Raises Concerns

Health
Bloomberg Business

Biogen's Spinraza: Great Launch, Rough Ride

Health Earnings
Xconomy

Biogen, Eisai Alzheimer’s Drug Fails First Test But Study Continues

Health Science
Xconomy

After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

Health Strategy
Xconomy

Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise

Health Earnings
BostInno

26 Lawsuits from Biogen | 26 Startups Raised $393M in June

Xconomy

Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M

Health
Xconomy

MS Drug Patent Rulings Give Biogen Win, Acorda Loss in Separate Suits

Legal Health
Xconomy

Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins

Health
Xconomy

Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof

Health
Xconomy

Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths

Health Strategy Stock markets
Xconomy

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

Health
Xconomy

Biogen to Pay $1.25B to Settle Forward Pharma Patent Suit on MS Drug

Legal
Xconomy

Families Fret As Insurers Mull Biogen's $750K Spine Disease Drug

Health
Xconomy

Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug

Health